1. Home
  2. SKYE vs SLNG Comparison

SKYE vs SLNG Comparison

Compare SKYE & SLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • SLNG
  • Stock Information
  • Founded
  • SKYE 2012
  • SLNG 2013
  • Country
  • SKYE United States
  • SLNG United States
  • Employees
  • SKYE N/A
  • SLNG N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • SLNG Oil/Gas Transmission
  • Sector
  • SKYE Health Care
  • SLNG Utilities
  • Exchange
  • SKYE Nasdaq
  • SLNG Nasdaq
  • Market Cap
  • SKYE 101.3M
  • SLNG 94.1M
  • IPO Year
  • SKYE N/A
  • SLNG N/A
  • Fundamental
  • Price
  • SKYE $3.29
  • SLNG $4.10
  • Analyst Decision
  • SKYE Buy
  • SLNG Strong Buy
  • Analyst Count
  • SKYE 7
  • SLNG 1
  • Target Price
  • SKYE $15.50
  • SLNG $10.00
  • AVG Volume (30 Days)
  • SKYE 313.7K
  • SLNG 8.6K
  • Earning Date
  • SKYE 08-07-2025
  • SLNG 08-06-2025
  • Dividend Yield
  • SKYE N/A
  • SLNG N/A
  • EPS Growth
  • SKYE N/A
  • SLNG N/A
  • EPS
  • SKYE N/A
  • SLNG 0.05
  • Revenue
  • SKYE N/A
  • SLNG $69,572,000.00
  • Revenue This Year
  • SKYE N/A
  • SLNG $8.97
  • Revenue Next Year
  • SKYE N/A
  • SLNG $6.90
  • P/E Ratio
  • SKYE N/A
  • SLNG $84.61
  • Revenue Growth
  • SKYE N/A
  • SLNG N/A
  • 52 Week Low
  • SKYE $1.14
  • SLNG $3.71
  • 52 Week High
  • SKYE $7.47
  • SLNG $8.28
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 44.67
  • SLNG 39.38
  • Support Level
  • SKYE $3.23
  • SLNG $4.06
  • Resistance Level
  • SKYE $3.75
  • SLNG $4.40
  • Average True Range (ATR)
  • SKYE 0.30
  • SLNG 0.23
  • MACD
  • SKYE -0.02
  • SLNG -0.04
  • Stochastic Oscillator
  • SKYE 29.76
  • SLNG 12.00

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

Share on Social Networks: